SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-023806
Filing Date
2024-02-14
Accepted
2024-02-14 16:30:42
Documents
16
Period of Report
2024-02-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm246184d2_8k.htm   iXBRL 8-K 30736
2 EXHIBIT 10.1 tm246184d2_ex10-1.htm EX-10.1 30694
  Complete submission text file 0001104659-24-023806.txt   288706

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20240209.xsd EX-101.SCH 3303
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20240209_def.xml EX-101.DEF 26897
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20240209_lab.xml EX-101.LAB 36508
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20240209_pre.xml EX-101.PRE 25521
17 EXTRACTED XBRL INSTANCE DOCUMENT tm246184d2_8k_htm.xml XML 5316
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 24639094
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)